WHY SPINRAZA/EARLY-ONSET STUDY

Considering treatment?
SPINRAZA has been studied for over a decade in the longest SMA clinical development program to date

SPINRAZA delivered powerful survival results and motor function improvement for children with SMA

In a pivotal trial, SPINRAZA achieved significant results in important milestones compared to untreated control group

Pivotal study: ENDEAR

Who: 121 children aged 7 months and younger with Type 1 (early-onset) SMA (80 children were treated with SPINRAZA versus 41 who were given a placebo)

Study time: 13 months

Primary outcomes:

  • Time to death or use of permanent assisted ventilation
  • The proportion of responders (or number of children) who showed an improvement in motor milestones according to HINE-2

Safety: The most common side effects were lower respiratory infection (55%; 44/80) and constipation (35%; 28/80). Serious adverse reactions of collapsed lung (atelectasis) were more frequent in the SPINRAZA-treated group (18%; 14/80) than in the control group (10%; 4/41).

Those with Type 1 SMA showed improvements in motor milestones that are rarely, if ever, achieved in untreated children

51% (37/73)
of children treated with SPINRAZA

VS

0% (0/37)
of the children in the untreated control group

were motor milestone responders according to HINE-2 at 13 months

Motor milestones included:

There was an overall 47% reduced risk of mortality or permanent ventilation in the SPINRAZA group versus the untreated group and a 63% reduced risk of mortality in the SPINRAZA group versus the untreated group

Sofia, age 2 in photo, wearing a pink tutu. Has SMA and has been treated with SPINRAZA for 6+ years.

“Whether she can or can't do
something, she's going to try.” Natalia, Sofia’s mom

Your healthcare provider will monitor for signs of bleeding
complications or kidney damage while you are taking SPINRAZA